Menu Icon Created with Sketch Beta.

Accelerating Drug Discovery and Development

Vium

Previous Post Left arrow Next Post Right Arrow

Vium improves the speed and reproducibility of preclinical research to better predict how drugs perform in humans. Vium was acquired by Recursion Pharmaceuticals in 2020.

Vium empowers biomedical investigators with technology that accelerates the preclinical drug discovery and development pipeline. Researchers can design, run, and analyze experiments that rapidly surface insights and high volumes of quality data. The result is that better therapies get moved more quickly through to patients who need them.

View All Companies